Nurix Therapeutics Says FDA Lifts Partial Clinical Hold On NX-2127 Phase 1 Trial
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the partial clinical hold on Nurix Therapeutics' NX-2127 Phase 1 trial, initially placed due to a transition to an improved manufacturing process. Nurix plans to resume enrollment with a new drug substance in the ongoing Phase 1a/1b trial.
March 11, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's decision to lift the partial clinical hold on Nurix's NX-2127 Phase 1 trial is a positive development, allowing the company to proceed with its planned enrollment using an improved drug substance.
The lifting of the FDA's partial clinical hold is a significant positive development for Nurix, indicating regulatory confidence in the company's revised manufacturing process and its NX-2127 drug. This move allows the company to advance its clinical trial, potentially accelerating the drug's development timeline and enhancing investor confidence in Nurix's pipeline.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100